Cross-tolerance and μ agonist efficacy in pigeons treated with LAAM or buprenorphine

Pharmacology Biochemistry and Behavior

Volumn 81, Issue 3, 2005, Pages 626-634

  Galici, R ^a,b   McMahon, L R ^a   France, C P ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Drug discrimination; Heroin; LAAM; Opioid; Tolerance

Indexed keywords

AMPHETAMINE; BUPRENORPHINE; COCAINE; DIAMORPHINE; ENADOLINE; KAPPA OPIATE RECEPTOR; LEVACETYLMETHADOL; MU OPIATE RECEPTOR AGONIST; NALBUPHINE; OPIATE; SODIUM CHLORIDE; SPIRADOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; BEHAVIOR; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG CROSS TOLERANCE; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEROIN DEPENDENCE; NONHUMAN; PIGEON; PRIORITY JOURNAL; SUBSTITUTION THERAPY;

ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; BUPRENORPHINE; COLUMBIDAE; DISCRIMINATION (PSYCHOLOGY); DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; HEROIN; METHADYL ACETATE; NALBUPHINE; RECEPTORS, OPIOID, MU; SODIUM CHLORIDE; TIME FACTORS;

COLUMBA;

EID: 22044441988     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2005.05.003     Document Type: Article

References (35)

1. L. Amass, W.K. Bickel, J.P. Crean, J. Blake, and S.T. Higgins Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans Psychopharmacology 136 1998 217 225
2. M.M. Belcheva, J. Barg, R.J. McHale, S. Dawn, M.T. Ho, and E. Ignatova Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine Mol Pharmacol 44 1993 173 179
3. D. Best, M. Gossop, D. Stewart, J. Marsden, P. Lehmann, and J. Strang Continued heroin use during methadone treatment: relationships between frequency of use and reasons reported for heroin use Drug Alcohol Depend 53 1999 191 195
4. W.K. Bickel, M.L. Stitzer, G.E. Bigelow, I.A. Liebson, D.R. Jasinski, and R.E. Johnson Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans J Pharmacol Exp Ther 247 1988 47 53
5. M.R. Brandt, and C.P. France Chronic l-alpha-acetylmethadol (LAAM) in rhesus monkeys: tolerance and cross-tolerance to the antinociceptive, ventilatory, and rate-decreasing effects of opioids J Pharmacol Exp Ther 294 2000 168 178
6. M.R. Brandt, S.R. Cabansag, and C.P. France Discriminative stimulus effects of l-alpha-acetylmethadol (LAAM), buprenorphine and methadone in morphine-treated rhesus monkeys J Pharmacol Exp Ther 282 1997 574 584
7. J.C. Chen, E.R. Smith, M. Cahill, R. Cohen, and J.B. Fishman The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine Life Sci 52 1993 389 396
8. F.C. Colpaert Drug discrimination: no evidence for tolerance to opiates Pharmacol Rev 47 1995 605 629
9. A. Cowan, J.W. Lewis, and I.R. Macfarlane Agonist and antagonist properties of buprenorphine, a new antinociceptive agent Br J Pharmacol 60 1977 537 545
10. M.W. Emmett-Oglesby, T.S. Shippenberg, and A. Herz Tolerance and cross-tolerance to the discriminative stimulus properties of fentanyl and morphine J Pharmacol Exp Ther 245 1988 17 23
11. C.P. France, A.E. Jacobson, and J.H. Woods Discriminative stimulus effects of reversible and irreversible opiate agonists: morphine, oxymorphazone and buprenorphine J Pharmacol Exp Ther 230 1984 652 657
12. R. Galici, R.M. Brandt, and C.P. France Characterization of the discriminative stimulus effects of buprenorphine in pigeons Psychopharmacology 160 2002 132 139
13. L.R. Gerak, and C.P. France Changes in sensitivity to the rate-decreasing effects of opioids in pigeons treated acutely or chronically with l-alpha-acetylmethadol J Pharmacol Exp Ther 281 1997 799 809
14. M.K. Greenwald, C.E. Johanson, D.E. Moody, J.H. Woods, M.R. Kilbourn, and R.A. Koeppe Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers Neuropsychopharmacology 28 2003 2000 2009
15. J.M. Hambrook, and M.J. Rance The interaction of buprenorphine with the opiate receptor: lipophilicity as a determining factor in drug-receptor kinetics H.W. Kosterlitz Opiates and endogenous opioid peptides 1976 Elsevier/North-Holland Biomedical Press Amsterdam 295 301
16. E.J. Houtsmuller, S.L. Walsh, K.J. Schuh, R.E. Johnson, M.L. Stitzer, and G.E. Bigelow Dose-response analysis of opioid cross-tolerance and withdrawal suppression during LAAM maintenance J Pharmacol Exp Ther 285 1998 387 396
17. M.J. Kreek Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine Ann N Y Acad Sci 909 2000 186 216
18. M.J. Kreek, and F.J. Vocci History and current status of opioid maintenance treatments: blending conference session J Subst Abuse Treat 23 2002 93 105
19. R. Levine, A. Zaks, M. Fink, and A.M. Freedman Levomethadyl acetate. Prolonged duration of opioid effects, including cross tolerance to heroin, in man JAMA 226 1973 316 318
20. W. Ling, and D.R. Wesson Clinical efficacy of buprenorphine: comparisons to methadone and placebo Drug Alcohol Depend 70 2003 S49 S57
21. W.R. Martin, C.G. Eades, J.A. Thompson, R.E. Huppler, and P.E. Gilbert The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog J Pharmacol Exp Ther 197 1976 517 532
22. J.C. Marvizon, E.F. Grady, J. Waszak-McGee, and E.A. Mayer Internalization of mu-opioid receptors in rat spinal cord slices Neuroreport 10 1999 2329 2334
23. D.E. McMillan, and M. Brocco Modification of drug effects by l-alpha-acetylmethadol Pharmacol Biochem Behav 20 1984 543 546
24. D. Parolaro, T. Rubino, E. Gori, P. Massi, C. Bendotti, and G. Patrini In situ hybridization reveals specific increases in G alpha s and G alpha o mRNA in discrete brain regions of morphine-tolerant rats Eur J Pharmacol 244 1993 211 222
25. C.A. Paronis, and S.G. Holtzman Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats J Pharmacol Exp Ther 262 1992 1 9
26. D.E. Selley, C.-C. Cao, Q. Liu, and S.R. Childers Effects of sodium on agonist efficacy for G-protein activation in μ-opioid receptor-transfected CHO cells and rat thalamus Br J Pharmacol 130 2000 987 996
27. D.E. Selley, C.-C. Cao, T. Sexton, J.A. Schwegel, T.J. Martin, and S.R. Childers μ Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine Biochem Pharmacol 62 2001 447 455
28. R.J. Tallarida, and A. Cowan The affinity of morphine for its pharmacologic receptor in vivo J Pharmacol Exp Ther 222 1982 198 201
29. S.K. Teoh, N.K. Mello, J.H. Mendelson, J. Kuehnle, D.R. Gastfriend, and E. Rhoades Buprenorphine effects on morphine- and cocaine-induced subjective responses by drug-dependent men J Clin Psychopharmacol 14 1994 15 27
30. J. Volavka, K. Verebey, R. Resnick, and S. Mule Methadone dose, plasma level, and cross-tolerance to heroin in man J Nerv Ment Dis 166 1978 104 109
31. E.A. Walker, and A.M. Young Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats Psychopharmacology 154 2001 131 142
32. E.A. Walker, and A.M. Young Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine J Pharmacol Exp Ther 302 2002 101 110
33. E.A. Walker, G. Zernig, and J.H. Woods Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure J Pharmacol Exp Ther 273 1995 1345 1352
34. A.M. Young, G. Kapitsopoulos, and M.M. Makhay Tolerance to morphine-like stimulus effects of mu opioid agonists J Pharmacol Exp Ther 257 1991 795 805
35. A. Zaks, M. Fink, and A.M. Freedman Duration of methadone induced cross-tolerance to heroin Br J Addict Alcohol Other Drugs 66 1971 205 208